Explore the Agenda
일정 확인하기
8:00 am Check-In & Morning Coffee
8:45 am Chair’s Opening Remarks
Achieving Best-in-Class mRNA Vaccines to Treat Infectious & Oncological Diseases to Ensure Equitable & Global Access
9:00 am R&D Trends in Post-Pandemic Era: Update in Novel Technology for Biologics Stockpile & Mobile Manufacturing Unit
- Discussing opportunities for post pandemic preparedness
- Harnessing vaccine stockpile technology
- Demonstrating mobile manufacturing systems
9:30 am The RIGHT Foundation’s Approach for Global Health R&D With Focus on Disease of Pandemic Potential
- Outline a strategy for global health R&D with end-to-end approach
- Explore a commitment for global health access with focus on health equity for infectious disease in low- and middle-income countries (LMICs)
- Discuss the scope of R&D funding support and upcoming opportunities for global health R&D
10:00 am Advancing Quality Excellence Across the mRNA–LNP Product Lifecycle
- Reviewing quality considerations across the mRNA–LNP lifecycle
- Assessing key product quality attributes
- Exploring emerging USP standards for mRNA therapeutics and vaccines
10:30 am Morning Coffee Break
11:00 am Networking Break
This networking session is your opportunity to get face-to-face with many of the brightest minds working in the mRNA, cell and gene fields and establish meaningful business relationships.
Developing a Robust mRNA Vaccine & Therapeutic Platform to Improve the Safety, Manufacturing & Development Across Applications
11:30 am Preclinical Study of a COVID-19 Vaccine Candidate Based on a Next-Generation Korean Self-Amplifying RNA (saRNA) Platform
- Exploring immunogenicity and protective efficacy of a next-generation self-amplifying RNA COVID-19 vaccine candidate
- Discussing biodistribution and nonclinical safety assessment supporting preclinical development
- Unveiling CMC development and process optimization toward clinical translation
12:00 pm Advancing mRNA Platform Technology for Innovative Vaccines & Therapeutics
- Outlining GC Biopharma’s mRNA Platform technology for better performance
- Showcasing next-generation mRNA constructs with proprietary patent-secured sequences, circular RNA and self-amplifying mRNA
- Discovering versatile applications of mRNA vaccines and therapeutics
12:30 pm Lunch Break
1:15 pm Extended Networking
The Next Wave: Advancing Next Generation RNA Discovery, Design & Platform Strategies to Achieve Better Dosing & Safety in Patients
1:45 pm Minimal Chemical Modification to the 3’-Poly(A) Terminus Elicit Durable Protein Expression of Linear mRNA in Mice & Non-Human Primates
- Overview of Eisai’s linear mRNA discovery platform
- Explore key advancements in stability and translation efficiency optimization
- Assess the platform potential and future directions for RNA technologies
2:15 pm Outlining BioPROTAC: A Novel TPD Payload In mRNA Therapy
- Unveil an update of EPDegTM bioPROTAC development
- Discuss the proved differentiating points of bioPROTAC platform from others
- Learn the current challenges and future directions
2:45 pm Organ- & Cell-Specific Translation Enabled by RNA Switch™ Technology
- Explore ON- and OFF-translational control using endogenous microRNAs as organ- and cell- specific markers
- Outline design principles for specific translation based on RNA Switch™ technology
- Discover immune cell–selective translation enabled by RNA Switches and its applications